Figure 1
Figure 2
Figure 3
Figure 4
Univariate and multivariate analysis
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| DFS | BC | DFS | BC | |||||
| Covariate: | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age | 0.99 (0.94, 1.04) | 0.59 | 1.03 (0.99, 1.08) | 0.14 | 0.97 (0.92, 1.02) | 0.19 | 1.02 (0.98, 1.07) | 0.34 |
| max PSA prior to operation | 1.03 (0.97, 1.08) | 0.35 | 1.03 (1, 1.07) | 0.078 | 1.04 (0.97, 1.11) | 0.25 | 1.05 (1.02, 1.08) | 0.001 |
| max PSA post operation | 1 (0.96, 1.05) | 0.91 | 1.04 (1.02, 1.05) | <.001 | 0.53 (0.28, 1.01) | 0.052 | 1 (0.99, 1.02) | 0.65 |
| PSA before radiotherapy | 1.24 (1.12, 1.37) | <.001 | 1.26 (1.17, 1.35) | <.001 | 2.17 (1.04, 4.55) | 0.04 | 1.19 (1.03, 1.38) | 0.017 |
| ADT prior to RT | 1.42 (0.74, 2.74) | 0.29 | 1.06 (0.64, 1.75) | 0.82 | 1.39 (0.69, 2.77) | 0.35 | 0.82 (0.5, 1.35) | 0.43 |
| pT3a-b vs. pT2a-c | 2.57 (1.29, 5.1) | 0.007 | 1.35 (0.83, 2.19) | 0.23 | 4.29 (1.8, 10.25) | 0.001 | 1.89 (1.02, 3.5) | 0.044 |
| pN0 vs pN1 | 0.58 (0.16, 2.13) | 0.42 | 0.94 (0.3, 2.99) | 0.92 | 0.82 (0.31, 2.19) | 0.69 | 0.98 (0.56, 1.72) | 0.95 |
| aRT indication - R1 | 0.6 (0.27, 1.31) | 0.2 | 0.36 (0.2, 0.64) | <.001 | 0.81 (0.19, 3.52) | 0.78 | 0.21 (0.09, 0.52) | 0.001 |
| aRT indication - pT3a-b | 1.45 (0.69, 3.04) | 0.33 | 0.86 (0.48, 1.55) | 0.62 | 0.72 (0.18, 2.89) | 0.64 | 1.04 (0.43, 2.53) | 0.93 |
| sRT indication - biochemical failure | 1.31 (0.64, 2.68) | 0.46 | 2.02 (1.17, 3.49) | 0.011 | 1.95 (0.41, 9.27) | 0.4 | 1.12 (0.52, 2.41) | 0.77 |
| sRT indication - local failure | 2.03 (1.06, 3.89) | 0.033 | 2.36 (1.45, 3.84) | 0.001 | 2.39 (1.11, 5.15) | 0.026 | 1.48 (0.77, 2.83) | 0.24 |
| R1 operation (regardless of RT indication) | 1.2 (0.61, 2.35) | 0.59 | 0.82 (0.5, 1.32) | 0.41 | 1.52 (0.59, 3.92) | 0.38 | 2.17 (1.23, 3.84) | 0.007 |
| PSA nadir (per 1ng/ml) | 1.34 (1.2, 1.5) | <.001 | 1.29 (1.19, 1.39) | <.001 | 1.16 (0.93, 1.46) | 0.19 | 1.37 (1.28, 1.46) | <.001 |
| Gleason Grade Group | 1.4 (1.09, 1.8) | 0.009 | 1.15 (0.96, 1.38) | 0.12 | 1.28 (0.95, 1.73) | 0.1 | 1.13 (0.93, 1.38) | 0.23 |
Description of the study group
| Whole group | aRT | sRT | |||
|---|---|---|---|---|---|
| Number of cases | 236 | 113 | 123 | ||
| Age* | 63.6 (59.8-68.4) | 62.3 (58.8-65.9) | 65.2 (60.5-70.2) | ||
| Time from surgery to RT (months)* | 6 (3.3-25.8) | 3.6 (2.9-4.8) | 24.1 (7.3-48.3) | ||
| Indication | n/a | R11 56 | pT32 57 | BCR3 69 | LF4 54 |
| Positive surgical margins | 61.5% | 100% | 77.2% | 39.1% | 27.8% |
| Max PSA pre-op* (ng/ml) | 9.16 (6.81-14.6) | 8.24 (6.33-11.78) | 9.37 (7.19-14.79) | 10.67 (7.3-17) | 8.8 (6.6-13.3) |
| Max PSA post-op*5 (ng/ml) | 0.27 (0.04-1.13) | 0.035 (<0.008-0.071) | 0.027 (<0.008-0.104) | 0.72 (0.38-1.92) | 1.19 (0.45 – 2.89) |
| PSA before RT* (ng/ml) | 0.2 (0.023-0.78) | 0.015 (<0.008-0.055) | 0.017 (<0.008-0.077) | 0.56 (0.29-1.07) | 1.05 (0.35-2.38) |
| Gleason Grade Group (post-op): | |||||
| 1 | 42.2% | 47.3% | 26.3% | 39.7% | 57.7% |
| 2 | 33.6% | 38.2% | 40.4% | 32.3% | 23.1% |
| 3 | 13.4% | 9.1% | 15.8% | 16.2% | 11.5% |
| 4 | 5.6% | 1.8% | 7% | 7.4% | 5.8% |
| 5 | 5.2% | 3.6% | 10.5% | 4.4% | 1.9% |
| TNM (post-op): | |||||
| pT2a-c | 61.6% | 100% | 0% | 63.6% | 84.3% |
| pT3a | 17.5% | 0% | 50.9% | 12.1% | 7.8% |
| pT3b | 21% | 0% | 49.1% | 24.2% | 7.8% |
| pN1 | 5.8% | 1.8% | 16.4% | 1.5% | 4% |
| ADT prior to RT | 37.6% | 16.4% | 43.9% | 42.6% | 46.3% |
| RT dose^ | 70 / 71.5 | 70 / 70.3 | 70 / 70.2 | 70 / 71.4 | 76 / 74.4 |
| Lymph node irradiation | 25.8% | 15% | 47.8% | 12.7% | 23.1% |